IMPAIRED PROLACTIN RESPONSE TO ARGININE IN PATIENTS WITH HYPERTHYROIDISM

被引:2
作者
CICCARELLI, E
ZINI, M
GROTTOLI, S
RAZZORE, P
PORTIOLI, I
VALCAVI, R
机构
[1] ARCISPEDALE S MARIA NUOVA,DIV MED INTERNA 2,I-42100 REGGIO EMILIA,ITALY
[2] ARCISPEDALE S MARIA NUOVA,SEZ ENDOCRINO METAB,I-42100 REGGIO EMILIA,ITALY
[3] UNIV TURIN,DIPARTIMENTO FISIOPATOL CLIN,DIV ENDOCRINOL,TURIN,ITALY
关键词
D O I
10.1111/j.1365-2265.1994.tb02559.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Reduced PRL responses to TRH or dopamine antagonists have been described in hyperthyroid patients. Arginine stimulates PRL secretion through pathways other than the activation of TRH receptors or dopamine-dependent mechanisms. We therefore investigated PRL responses to arginine in patients with hyperthyroidism. DESIGN L-Arginine (30 g infused over 30 minutes) was administered at time zero. SUBJECTS Sixteen patients with untreated hyperthyroidism due to Graves' disease (8 female and 8 male), with a mean age (+/- SE) of 31.3 +/- 1.4 years (range 23-42), and 12 normal subjects (6 female and 6 male, ages 30.1 +/- 2.1 years, range 22-47) were studied. MEASUREMENTS Prolactin was measured by RIA between -30 and 120 minutes, at 15-minute intervals. RESULTS Basal PRL levels were similar in the hyperthyroid patients and normal control subjects. The hyperthyroid women showed blunted PRL responses compared to normal women (peak PRL levels, 364 +/- 44 mU/l, vs 760 +/- 156, P < 0.02). PRL responses to arginine, small but clearly detectable in normal men, were completely abolished in hyperthyroid men (peak PRL levels, 248 +/- 48 mU/l, vs 112 +/- 14, P < 0.01). CONCLUSIONS PRL responses to arginine are impaired in hyperthyroid patients. Therefore; arginine should be added to the list of PRL stimuli whose responses are blunted in hyperthyroidism. Inhibition of PRL gene expression, and thus reduced pituitary PRL synthesis
引用
收藏
页码:371 / 374
页数:4
相关论文
共 27 条
[1]   ARGININE STIMULATES GROWTH-HORMONE SECRETION BY SUPPRESSING ENDOGENOUS SOMATOSTATIN SECRETION [J].
ALBAROTH, J ;
MULLER, OA ;
SCHOPOHL, J ;
VONWERDER, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (06) :1186-1189
[2]   DOPAMINERGIC MODULATION OF ARGININE MEDIATED GROWTH-HORMONE AND PROLACTIN-RELEASE IN MAN [J].
BANSAL, S ;
LEE, LA ;
WOOLF, PD .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1981, 30 (07) :649-653
[3]   DOPAMINE INFUSION ACUTELY INHIBITS TSH AND PROLACTIN RESPONSE TO TRH [J].
BESSES, GS ;
BURROW, GN ;
SPAULDING, SW ;
DONABEDIAN, RK .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1975, 41 (05) :985-988
[4]   MULTIHORMONAL REGULATION OF THE HUMAN, RAT, AND BOVINE GROWTH-HORMONE PROMOTERS - DIFFERENTIAL-EFFECTS OF 3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE, THYROID-HORMONE, AND GLUCOCORTICOIDS [J].
BRENT, GA ;
HARNEY, JW ;
MOORE, DD ;
LARSEN, PR .
MOLECULAR ENDOCRINOLOGY, 1988, 2 (09) :792-798
[5]   PROLACTIN-RELEASING EFFECT OF DOMPERIDONE IN NORMOPROLACTINEMIC AND HYPERPROLACTINEMIC SUBJECTS [J].
CAMANNI, F ;
GENAZZANI, AR ;
MASSARA, F ;
LAROSA, R ;
COCCHI, D ;
MULLER, EE .
NEUROENDOCRINOLOGY, 1980, 30 (01) :2-6
[6]   PHYSIOLOGY OF GROWTH-HORMONE SECRETION AND ACTION [J].
CASANUEVA, FF .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1992, 21 (03) :483-517
[7]  
CATTINI PA, 1986, J BIOL CHEM, V261, P3367
[8]   THYROID HORMONE-RESPONSIVE ELEMENTS OF THE PROLACTIN GENE - EVIDENCE FOR BOTH POSITIVE AND NEGATIVE REGULATION [J].
DAY, RN ;
MAURER, RA .
MOLECULAR ENDOCRINOLOGY, 1989, 3 (06) :931-938
[9]  
EHRFURTH EV, 1988, ACTA ENDOCRINOL-COP, V117, P241
[10]  
FEEK CM, 1981, J CLIN ENDOCRINOLOGY, V51, P585